Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hypersensitivity Clear all
Completed Phase 2 Interventional Results available

Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair

NCT00927758
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Gainesville, Florida • Iowa City, Iowa • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 11, 2026, 8:23 AM EDT
Completed No phase listed Observational Results available

Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema

NCT01059526
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
ecallantide
Drug
Lead sponsor
Shire
Industry
Eligibility
16 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
40
States / cities
Little Rock, Arkansas • Bell Gardens, California • Granada Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis

NCT00244543
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
R89674 (generic name not yet established)
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
10 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
North Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Sep 11, 2026, 8:23 AM EDT
Not listed No phase listed Observational

Intravenous Terbutaline in Severe Status Asthmaticus

NCT00750568
View directory record Official record
Conditions
Status Asthmaticus
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
2 Years to 18 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Louisville, Kentucky • Detroit, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2008 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

NCT03706040
View directory record Official record
Conditions
Dermatitis
Interventions
Placebo, Risankizumab
Biological
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Sep 11, 2026, 8:23 AM EDT
Active, not recruiting Phase 2 Interventional

Preventing Asthma in High Risk Kids

NCT02570984
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
24 Months to 47 Months
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
13
States / cities
Phoenix, Arizona • San Diego, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional

Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) Infection

NCT00000955
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Tuberculin Purified Protein Derivative
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
14
States / cities
New Haven, Connecticut • Wilmington, Delaware • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

Sunitinib in Never-Smokers With Lung Adenocarcinoma

NCT01829217
View directory record Official record
Conditions
Lung Cancer
Interventions
Sunitinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional Results available

Investigation of the Role of Pictorial Asthma Action Plans to Promote Self-management in Rural Youth With Asthma

NCT03187119
View directory record Official record
Conditions
Asthma
Interventions
Pictorial Asthma Action Plan, Written Asthma Action Plan
Behavioral
Lead sponsor
West Virginia University
Other
Eligibility
8 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Sep 11, 2026, 8:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Atopic Dermatitis With Accelerometry and Polysomnography (ADAP)

NCT05583019
View directory record Official record
Conditions
Atopic Dermatitis, Eczema, Healthy
Interventions
GENEActiv Accelerometry Device, Centrepoint Insights Watch (CPIW) Accelerometry Device, Apple Watch Accelerometry Device, Polysomnography, Videography
Device
Lead sponsor
SymmetryScience Group, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Randomized, Crossover Study to Assess the Effects of Dietary Fiber-containing Bars on Glucose and Insulin Responses

NCT03796286
View directory record Official record
Conditions
Blood Glucose, Insulin Sensitivity, Dietary Fiber
Interventions
Medium-fiber bar, High-fiber bar, Control bar (0 g fiber)
Other
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Boca Raton, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Sep 11, 2026, 8:23 AM EDT
Completed No phase listed Observational

Systemic Reactions to Allergen Immunotherapy Amd Skin Testing

NCT00594802
View directory record Official record
Conditions
SYSTEMIC REACTION
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 8, 2010 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

NCT04191096
View directory record Official record
Conditions
Metastatic Hormone-Sensitive Prostate Cancer
Interventions
Pembrolizumab, Enzalutamide, Androgen Deprivation Therapy (ADT), Placebo
Biological · Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
27
States / cities
Anchorage, Alaska • Duarte, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 11, 2026, 8:23 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Allergy and Immunology Natural History Study

NCT05584488
View directory record Official record
Conditions
Immune Deficiency, Immune Dysregulation Disorder, Allergic Inflammation
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
Up to 99 Years
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 11, 2026, 8:23 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Pilot Study to Assess the Suitability of the HealthBeacon Injection Care Management System (ICMS) as a Remote Therapeutic Monitoring (RTM) Device

NCT05592769
View directory record Official record
Conditions
Respiratory Disease
Interventions
HealthBeacon Injection Care Management System (ICMS)
Device
Lead sponsor
HealthBeacon Plc
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Sep 11, 2026, 8:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Nitric Oxide, LPS and the Pathogenesis of Asthma Phase 1

NCT00671229
View directory record Official record
Conditions
Healthy, Asthma
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 40 Years
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 11, 2026, 8:23 AM EDT
Active, not recruiting No phase listed Observational

NIOSH R21 WTC Asthma

NCT07222501
View directory record Official record
Conditions
Asthma
Interventions
SaMBA, Asthma Education - WTC Related
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 11, 2026, 8:23 AM EDT
Not listed No phase listed Observational

Phenotyping Asthma for Bronchial Thermoplasty

NCT03435237
View directory record Official record
Conditions
Severe Asthma
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 1 Interventional

Clinical Trial of STAHIST in Seasonal Allergic Rhinitis Patients

NCT00932256
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
STAHIST NDC #58407-536-01
Drug
Lead sponsor
Magna Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 7, 2010 · Synced Sep 11, 2026, 8:23 AM EDT
Withdrawn Phase 4 Interventional

Manuka Eye Droops for Treatment of Allergy

NCT03862053
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Manuka honey
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Germantown, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional

Improving Asthma Outcomes in an Urban Pediatric Population

NCT00140439
View directory record Official record
Conditions
Asthma
Interventions
Emergency Department based asthma follow-up clinic
Behavioral
Lead sponsor
Stephen J. Teach, MD, MPH
Other
Eligibility
12 Months to 17 Years
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma

NCT02554786
View directory record Official record
Conditions
Asthma
Interventions
Indacaterol acetate/Mometasone furoate, Mometasone furoate, Salmeterol xinafoate/fluticasone propionate
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
2,216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Sep 11, 2026, 8:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of T-Regulatory Cells in Asthma

NCT02574351
View directory record Official record
Conditions
Asthma
Interventions
blood draw, breathing test
Biological
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Results available

Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis

NCT03793439
View directory record Official record
Conditions
Sarcoidosis, Pulmonary, Sarcoidosis Lung, Sarcoidosis
Interventions
Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial, Spirometry, RNA Sequencing, Laboratory testing, Corticosteroid, Tofacitinib 5mg [Xeljanz] 1 year open-label extension
Drug · Diagnostic Test · Genetic
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 89 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Sep 11, 2026, 8:23 AM EDT